Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

PURPOSE: BCL2 overexpression is a hallmark of chronic lymphocytic leukemia (CLL). The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and related proteins BCL-x(l) and BCL-w, potently inducing apoptosis of CLL cells in vitro. A phase I trial in patients with CLL was conducted to ev...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Clin Oncol
Huvudupphovsmän: Roberts, Andrew W., Seymour, John F., Brown, Jennifer R., Wierda, William G., Kipps, Thomas J., Khaw, Seong Lin, Carney, Dennis A., He, Simon Z., Huang, David C.S., Xiong, Hao, Cui, Yue, Busman, Todd A., McKeegan, Evelyn M., Krivoshik, Andrew P., Enschede, Sari H., Humerickhouse, Rod
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Clinical Oncology 2012
Ämnen:
ORIGINAL REPORTS
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979082/
https://ncbi.nlm.nih.gov/pubmed/22184378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.34.7898
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk